Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
143.31
-0.40 (-0.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
Next >
Alnylam Pharmaceuticals's Return On Capital Employed Insights
February 27, 2023
Via
Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
February 24, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
February 21, 2023
Via
Benzinga
Five Best And Worst Performing Healthcare Stocks In December 2022
January 22, 2023
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst...
Via
Talk Markets
Alnylam's Lumasiran Scores Expanded FDA Approval For Ultra Rare Genetic Disease
October 07, 2022
Via
Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
October 03, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Alnylam Reinforces Patisiran Data In Stiff Heart Disorder Before Heading For FDA Approval
October 03, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
January 18, 2023
Via
Benzinga
3 Growth Stocks That Could Rocket Higher in 2023
January 06, 2023
Upcoming binary events could push these stocks to new all-time highs.
Via
The Motley Fool
Meta To Rally Over 29%? Here Are 10 Other Price Target Changes For Friday
December 16, 2022
Via
Benzinga
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
December 06, 2022
Via
Benzinga
Looking Into Alnylam Pharmaceuticals's Return On Capital Employed
November 02, 2022
Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q3 sales of $264.31 million. Earnings fell to a loss of $405.92 million, resulting in a 46.33% decrease from last quarter.
Via
Benzinga
What 11 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
November 02, 2022
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:
Via
Benzinga
Alnylam Scraps Interim Analysis For Heart Disease Trial, Rethinks Plans For Another Rare Disorder Program
October 27, 2022
Via
Benzinga
Alnylam Pharmaceuticals: Q3 Earnings Insights
October 27, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q3 earnings results on Thursday, October 27, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
October 20, 2022
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Via
Investor's Business Daily
Where Alnylam Pharmaceuticals Stands With Analysts
October 13, 2022
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:
Via
Benzinga
Roblox To $51? Plus Deutsche Bank Slashes PT On Deere & Company
October 13, 2022
Via
Benzinga
3 Top Biotech Stocks Defying the Bear Market
October 11, 2022
Bear market, shmear market. These biotech stocks are soaring despite the market downturn.
Via
The Motley Fool
Where Alnylam Pharmaceuticals Stands With Analysts
October 03, 2022
Over the past 3 months, 12 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
What 12 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
October 03, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:
Via
Benzinga
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
October 02, 2022
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 22, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Analysts Put Alnylam On Upside Catalyst Watch Ahead Of Upcoming Data From Lead Program
September 20, 2022
Via
Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
September 16, 2022
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.
Via
Investor's Business Daily
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
September 15, 2022
Via
Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
Alnylam/Regeneron-Backed NASH Candidate Shows Encouraging Safety Profile In Healthy Volunteers
September 15, 2022
Via
Benzinga
Why Alnylam Pharmaceuticals Shares Are Falling
September 12, 2022
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares are trading lower by 4.97% to $212.18 Monday morning after the company announced a proposed offering of $900 million convertible
Via
Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
September 09, 2022
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.